These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8556396)

  • 1. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
    Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
    N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
    Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
    Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
    Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
    Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.
    Jacobson MA; De Gruttola V; Reddy M; Arduino JM; Strickland S; Reichman RC; Bartlett JA; Phair JP; Hirsch MS; Collier AC
    AIDS; 1995 Jul; 9(7):727-34. PubMed ID: 7546418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.